000285734 001__ 285734
000285734 005__ 20260320145858.0
000285734 0247_ $$2doi$$a10.1002/alz.71296
000285734 0247_ $$2pmid$$apmid:41859776
000285734 0247_ $$2ISSN$$a1552-5260
000285734 0247_ $$2ISSN$$a1552-5279
000285734 037__ $$aDZNE-2026-00291
000285734 041__ $$aEnglish
000285734 082__ $$a610
000285734 1001_ $$0P:(DE-2719)9001249$$aWagemann, Olivia$$b0$$eFirst author
000285734 245__ $$aCombining blood biomarkers and the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-G) for diagnosing cognitive decline in Down syndrome.
000285734 260__ $$aHoboken, NJ$$bWiley$$c2026
000285734 3367_ $$2DRIVER$$aarticle
000285734 3367_ $$2DataCite$$aOutput Types/Journal article
000285734 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1774014942_12446
000285734 3367_ $$2BibTeX$$aARTICLE
000285734 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285734 3367_ $$00$$2EndNote$$aJournal Article
000285734 520__ $$aIndividuals with Down syndrome (DS) are at risk for Alzheimer's disease (AD). However, diagnosis remains challenging due to variability of intellectual ability and symptom presentation. To investigate whether serum AD biomarkers enhance accuracy of the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-G), we combined test scores with neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels.Seventy-eight DS individuals (49% female) completed the DSQIID-G; previous cohort data were added for a pooled sample (n = 164, 47% female). Serum NfL and GFAP were assessed using the automated microfluid Ella system.Combining the DSQIID-G with NfL or GFAP resulted in improved accuracy in every diagnostic subgroup. The Youden index in the pooled samples yielded a cut-off score at 6.5.The DSQIID-G is a robust screening tool and its combination with AD blood biomarkers aids earlier identification of individuals requiring further diagnostics for DS-associated AD.
000285734 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285734 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285734 650_7 $$2Other$$aAlzheimer's disease
000285734 650_7 $$2Other$$aDementia Screening Questionnaire for Individuals with Intellectual Disabilities
000285734 650_7 $$2Other$$aDown syndrome
000285734 650_7 $$2Other$$ablood biomarker
000285734 650_7 $$2Other$$aglial fibrillary acidic protein
000285734 650_7 $$2Other$$aneurofilament light chain
000285734 650_7 $$2Other$$ascreening
000285734 650_7 $$2NLM Chemicals$$aBiomarkers
000285734 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000285734 650_7 $$2NLM Chemicals$$aneurofilament protein L
000285734 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000285734 650_2 $$2MeSH$$aHumans
000285734 650_2 $$2MeSH$$aDown Syndrome: complications
000285734 650_2 $$2MeSH$$aDown Syndrome: blood
000285734 650_2 $$2MeSH$$aFemale
000285734 650_2 $$2MeSH$$aMale
000285734 650_2 $$2MeSH$$aBiomarkers: blood
000285734 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000285734 650_2 $$2MeSH$$aMiddle Aged
000285734 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000285734 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000285734 650_2 $$2MeSH$$aSurveys and Questionnaires
000285734 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000285734 650_2 $$2MeSH$$aGermany
000285734 650_2 $$2MeSH$$aIntellectual Disability: blood
000285734 650_2 $$2MeSH$$aIntellectual Disability: complications
000285734 650_2 $$2MeSH$$aAged
000285734 650_2 $$2MeSH$$aDementia: diagnosis
000285734 650_2 $$2MeSH$$aDementia: blood
000285734 650_2 $$2MeSH$$aAdult
000285734 7001_ $$aGötz, Charlotte$$b1
000285734 7001_ $$aWlasich, Elisabeth$$b2
000285734 7001_ $$aSandkühler, Katja$$b3
000285734 7001_ $$0P:(DE-2719)9001508$$aPrix, Catharina$$b4$$udzne
000285734 7001_ $$0P:(DE-2719)9002610$$aStockbauer, Anna$$b5$$udzne
000285734 7001_ $$0P:(DE-2719)9003208$$aMarth, Lena$$b6$$udzne
000285734 7001_ $$0P:(DE-2719)9002626$$aJäck, Alexander$$b7$$udzne
000285734 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b8$$udzne
000285734 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b9$$udzne
000285734 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b10$$udzne
000285734 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b11$$udzne
000285734 7001_ $$0P:(DE-2719)9001761$$aNübling, Georg$$b12$$eLast author$$udzne
000285734 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.71296$$gVol. 22, no. 3, p. e71296$$n3$$pe71296$$tAlzheimer's and dementia$$v22$$x1552-5260$$y2026
000285734 8564_ $$uhttps://pub.dzne.de/record/285734/files/DZNE-2026-00291.pdf$$yRestricted
000285734 8564_ $$uhttps://pub.dzne.de/record/285734/files/DZNE-2026-00291.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001249$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285734 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001508$$aExternal Institute$$b4$$kExtern
000285734 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002610$$aExternal Institute$$b5$$kExtern
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003208$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285734 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002626$$aExternal Institute$$b7$$kExtern
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285734 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b9$$kExtern
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285734 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001761$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000285734 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285734 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-11$$wger
000285734 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285734 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285734 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285734 980__ $$ajournal
000285734 980__ $$aEDITORS
000285734 980__ $$aVDBINPRINT
000285734 980__ $$aI:(DE-2719)1111015
000285734 980__ $$aUNRESTRICTED